Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Klaus Nagels"'
Publikováno v:
BMC Digital Health, Vol 2, Iss 1, Pp 1-16 (2024)
Abstract Introduction Neuromuscular diseases (NMDs) entail a group of mostly inherited genetic disorders with heterogeneous phenotypes impacting muscles, the central or peripheral nervous system. They can lead to severe disabilities and shortened lif
Externí odkaz:
https://doaj.org/article/7abe372043494007a5b3981f9eb99597
Autor:
Lena Schinner, Klaus Nagels, Julia Scherf, Christoph Schmaderer, Uwe Heemann, Claudius Küchle, Liya Hannemann
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background Sarcopenia is highly prevalent in haemodialysis (HD) patients and linked to a poor prognosis regarding comorbidities and premature mortality. Previous studies assessed the effects of neuromuscular electrical stimulation in haemodi
Externí odkaz:
https://doaj.org/article/aaadfd1a613742d18334bfe5a6cb6205
Publikováno v:
Monitor Versorgungsforschung, Vol 2022, Iss 06, Pp 40-43 (2022)
Die digitale Transformation in der Medizin versetzt uns in die Lage, immer größere und komplexere Datenmengen in verwertbares Wissen zu verwandeln. Die klassische medizinische Evidenzgenerierung wird dadurch zunehmend ergänzt oder sogar teilweise
Externí odkaz:
https://doaj.org/article/f2dd52902ca64f13a67da18c6573e6bd
Autor:
Prof. Dr. Dr. Klaus Nagels
Publikováno v:
Monitor Versorgungsforschung, Vol 2022, Iss 05, Pp 39-41 (2022)
Die Service-Dominant Logic kann vor dem Hintergrund der Digitalisierung der Versorgung als Strukturierungsrahmen wissenschaftlich in der Versorgungsforschung eingesetzt werden. In Deutschland sind die Grundlagen der Service-Dominant Logic, deren Anwe
Externí odkaz:
https://doaj.org/article/496004bde93f425ebc78453435cad3b3
Autor:
Klaus Nagels, Fabienne Englmeier
Publikováno v:
Monitor Versorgungsforschung. 13:62-68
Autor:
Heinz Völler, Dominik Bindl, Klaus Nagels, Reiner Hofmann, Eik Vettorazzi, Karl Wegscheider, Eckart Fleck, Stefan Störk, Eckhard Nagel
Publikováno v:
Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
Autor:
Fabienne Englmeier, Annalen Bleckmann, Wolfgang Brückl, Frank Griesinger, Annette Fleitz, Klaus Nagels
Publikováno v:
Journal of cancer research and clinical oncology.
Purpose Targeted therapies are effective therapeutic approaches in advanced stages of NSCLC and require precise molecular profiling to identify oncogenic drivers. Differential diagnosis on a molecular level contributes to clinical decision making. Li
Autor:
Sabine Krause, Olivia Schreiber-Katz, Elisabeth Schorling, Laura Gumbert, Maggie C. Walter, Peter Reilich, Katja Senn, Klaus Nagels, Simone Thiele
Publikováno v:
Journal of neuromuscular diseases. 9(1)
Background Charcot-Marie-Tooth (CMT) neuropathies entail a large group of diseases with different gene mutation patterns, which produce heterogeneous phenotypes. Although health-related quality of life (HRQOL) is significantly impaired, a comprehensi
Autor:
Melanie Runge, Klaus Nagels, M. Krensel, Claudia Westermann, Albert Nienhaus, Matthias Augustin, Dominik Bindl
Publikováno v:
International Journal of Environmental Research and Public Health, Vol 17, Iss 2, p 440 (2020)
International Journal of Environmental Research and Public Health
Volume 17
Issue 2
International Journal of Environmental Research and Public Health
Volume 17
Issue 2
Around 1% of the world&rsquo
s population is infected with hepatitis C. The introduction of new direct-acting antiviral agents (DAAs) in 2014 has substantially improved hepatitis C treatment outcomes. Our objective was to evaluate the long-term
s population is infected with hepatitis C. The introduction of new direct-acting antiviral agents (DAAs) in 2014 has substantially improved hepatitis C treatment outcomes. Our objective was to evaluate the long-term
Autor:
Yolande Lievens, Klaus Nagels
Publikováno v:
Radiotherapy and Oncology. 128:19-25
Background In the light of scarce resources to be allocated for cancer care and a steady stream of costly innovations in all modalities applied to treat cancer, particle therapy needs to demonstrate its cost-utility balance to allow its positioning i